## Annette M Molinaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7111330/publications.pdf

Version: 2024-02-01

101 papers

8,060 citations

36 h-index 51608 86 g-index

104 all docs

104 docs citations

times ranked

104

12823 citing authors

#	Article	IF	CITATIONS
1	Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. Journal of the National Cancer Institute, 2022, 114, 446-457.	6.3	11
2	Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging. Neuro-Oncology, 2022, 24, 639-652.	1.2	22
3	External controls to improve on glioblastoma clinical trials. Neuro-Oncology, 2022, 24, 257-258.	1.2	1
4	Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes. Clinical Epigenetics, 2022, 14, 14.	4.1	13
5	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. Journal of Clinical Investigation, 2022, 132, .	8.2	32
6	Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. Nature Communications, 2022, 13, 761.	12.8	93
7	Categorizing continuous biomarkers: More cons than pros. Neuro-Oncology Practice, 2022, 9, 81-82.	1.6	O
8	A core of differentially methylated CpG loci in gMDSCs isolated from neonatal and adult sources. Clinical Epigenetics, 2022, 14, 27.	4.1	2
9	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro-Oncology, 2022, 24, 1471-1481.	1.2	14
10	Regression trees and ensembles for cumulative incidence functions. International Journal of Biostatistics, 2022, 18, 397-419.	0.7	1
11	Prospective genomically guided identification of "early/evolving―and "undersampled―IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	1.2	10
12	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery, 2022, 90, 124-130.	1.1	17
13	Reducing complication rates for repeat craniotomies in glioma patients: a single-surgeon experience and comparison with the literature. Acta Neurochirurgica, 2022, 164, 405-417.	1.7	6
14	Skin disease in goats ( <i>Capra aegagrus hircus</i> ): a retrospective study of 358 cases at a university veterinary teaching hospital (1988–2020). Veterinary Dermatology, 2022, 33, 227.	1.2	6
15	The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival. American Journal of Human Genetics, 2022, 109, 1105-1116.	6.2	7
16	Pre-surgery immune profiles of adult glioma patients. Journal of Neuro-Oncology, 2022, 159, 103-115.	2.9	7
17	Prognostic risk stratification of gliomas using deep learning in digital pathology images. Neuro-Oncology Advances, 2022, 4, .	0.7	3
18	Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor. Radiotherapy and Oncology, 2021, 154, 145-153.	0.6	11

#	Article	IF	CITATIONS
19	The Relationship Between Stimulation Current and Functional Site Localization During Brain Mapping. Neurosurgery, 2021, 88, 1043-1050.	1.1	4
20	Smoking Is an Independent Risk Factor for 90-Day Readmission and Reoperation Following Posterior Cervical Decompression and Fusion. Neurosurgery, 2021, 88, 1088-1094.	1.1	10
21	Identification of a foetal epigenetic compartment in adult human kidney. Epigenetics, 2021, , 1-21.	2.7	О
22	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade <i>IDH</i> -mutant gliomas. Neuro-Oncology, 2021, 23, 1872-1884.	1.2	48
23	Relationship between 7T MR-angiography features of vascular injury and cognitive decline in young brain tumor patients treated with radiation therapy. Journal of Neuro-Oncology, 2021, 153, 143-152.	2.9	3
24	A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. Journal of Neuro-Oncology, 2021, 153, 447-454.	2.9	6
25	Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. Scientific Reports, 2021, 11, 12162.	3.3	28
26	Correlation of natural language assessment results with health-related quality of life in adult glioma patients. Journal of Neurosurgery, 2021, , $1$ -7.	1.6	2
27	Residual Tumor Volume and Location Predict Progression After Primary Subtotal Resection of Sporadic Vestibular Schwannomas: A Retrospective Volumetric Study. Neurosurgery, 2020, 86, 410-416.	1.1	22
28	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro-Oncology Advances, 2020, 2, vdaa142.	0.7	35
29	Adult diffuse glioma GWAS by molecular subtype identifies variants in <i>D2HGDH</i> and <i>FAM20C</i> . Neuro-Oncology, 2020, 22, 1602-1613.	1.2	19
30	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-Oncology, 2020, 22, 1580-1590.	1.2	55
31	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. Journal of Neuro-Oncology, 2020, 148, 131-139.	2.9	15
32	Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2020, 6, 495.	7.1	325
33	Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Neuro-Oncology, 2020, 22, 1516-1526.	1.2	5
34	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	8.2	70
35	Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget, 2020, 11, 1942-1952.	1.8	45
36	Phase I trial of caudate deep brain stimulation for treatment-resistant tinnitus. Journal of Neurosurgery, 2020, 133, 992-1001.	1.6	13

#	Article	IF	Citations
37	The impact of obesity on perioperative complications in patients undergoing anterior lumbar interbody fusion. Journal of Neurosurgery: Spine, 2020, 33, 332-341.	1.7	16
38	TAMI-07. THE IMMUNE MICROENVIRONMENT IN LOWER GRADE GLIOMAS. Neuro-Oncology, 2020, 22, ii214-ii214.	1.2	0
39	An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neuro-Oncology Advances, 2019, 1, vdz007.	0.7	40
40	EGFR amplification status for clinical trial inclusion: where do we draw the line?. Neuro-Oncology, 2019, 21, 1215-1216.	1.2	1
41	Risk factors of radiotherapyâ€induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. Journal of Magnetic Resonance Imaging, 2019, 50, 868-877.	3.4	25
42	Genetic and molecular epidemiology of adult diffuse glioma. Nature Reviews Neurology, 2019, 15, 405-417.	10.1	437
43	Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neuro-Oncology Practice, 2019, 6, 364-374.	1.6	16
44	Using germline variants to estimate glioma and subtype risks. Neuro-Oncology, 2019, 21, 451-461.	1.2	23
45	Longer genotypically-estimated leukocyte telomere length is associated with increased meningioma risk. Journal of Neuro-Oncology, 2019, 142, 479-487.	2.9	11
46	Temporal Dynamics of Pseudoprogression After Gamma Knife Radiosurgery for Vestibular Schwannomasâ€"A Retrospective Volumetric Study. Neurosurgery, 2019, 84, 123-131.	1.1	39
47	Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications. Neurosurgery, 2018, 83, 1161-1172.	1.1	29
48	Novel Aggregate Deletion/Substitution/Addition Learning Algorithms for Recursive Partitioning. Journal of Computational and Graphical Statistics, 2018, 27, 146-156.	1.7	0
49	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical Cancer Research, 2018, 24, 295-305.	7.0	68
50	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. Journal of Neuro-Oncology, 2018, 136, 33-39.	2.9	4
51	Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas. Translational Oncology, 2018, 11, 941-949.	3.7	8
52	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Journal of Neuro-Oncology, 2018, 140, 477-483.	2.9	82
53	Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma. Neurosurgery, 2018, 82, 64-75.	1.1	22
54	A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemotherapy and Pharmacology, 2017, 79, 603-610.	2.3	32

#	Article	IF	Citations
55	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	7.7	245
56	Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clinical Epigenetics, 2017, 9, 10.	4.1	60
57	Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure. Neurosurgery, 2017, 81, 824-833.	1.1	30
58	Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Scientific Reports, 2017, 7, 44792.	3.3	63
59	Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Radiation Research, 2017, 188, 303.	1.5	10
60	Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10743-10748.	7.1	109
61	Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery, 2017, 80, 129-139.	1.1	33
62	Probing the phosphatidylinositol 3â€kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult lowâ€grade gliomas. Cancer, 2017, 123, 4631-4639.	4.1	43
63	Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Translational Oncology, 2017, 10, 895-903.	3.7	15
64	Phase I cancer clinical trialsâ€. Neuro-Oncology Practice, 2017, 4, 67-72.	1.6	3
65	Clinical trial endpoints for patients with gliomas. Neuro-Oncology Practice, 2017, 4, 201-208.	1.6	7
66	GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget, 2016, 7, 79101-79116.	1.8	39
67	PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. International Journal of Cancer, 2016, 139, 99-111.	5.1	25
68	Doubly robust survival trees. Statistics in Medicine, 2016, 35, 3595-3612.	1.6	24
69	Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Research and Treatment, 2016, 157, 351-361.	2.5	15
70	Comparative Sensitivity of Intraoperative Motor Evoked Potential Monitoring in Predicting Postoperative Neurologic Deficits: Nondegenerative versus Degenerative Myelopathy. Global Spine Journal, 2016, 6, 452-458.	2.3	10
71	Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro-Oncology, 2016, 18, now163.	1.2	33
72	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology, 2016, 130, 543-552.	2.9	90

#	Article	IF	CITATIONS
73	Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro-Oncology, 2016, 18, 1169-1179.	1.2	28
74	Statistical considerations on prognostic models for glioma. Neuro-Oncology, 2016, 18, 609-623.	1.2	20
75	Understanding inherited genetic risk of adult glioma – a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.6	62
76	The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro-Oncology, 2016, 18, 87-95.	1.2	33
77	Surgical assessment of the insula. Part 2: validation of the Berger-Sanai zone classification system for predicting extent of glioma resection. Journal of Neurosurgery, 2016, 124, 482-488.	1.6	65
78	<i>CDKN2A</i> Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health) Tj ETQq0 0 0 2015, 74, 442-452.	rgBT /Over 1.7	lock 10 Tf 50 144
79	New initiative for Neuro-Oncology Practice: statistics for the practicing clinician. Neuro-Oncology Practice, 2015, 2, 161-161.	1.6	2
80	The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery, 2015, 77, 248-253.	1.1	47
81	Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. Journal of Neurosurgery, 2015, 123, 373-386.	1.6	247
82	Glioma Groups Based on 1p/19q, <i>IDH</i> , and <i>TERT</i> Promoter Mutations in Tumors. New England Journal of Medicine, 2015, 372, 2499-2508.	27.0	1,632
83	Diagnostic tests: how to estimate the positive predictive value. Neuro-Oncology Practice, 2015, 2, 162-166.	1.6	30
84	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Translational Oncology, 2015, 8, 446-455.	3.7	3
85	The Genetics of Splicing in Neuroblastoma. Cancer Discovery, 2015, 5, 380-395.	9.4	20
86	Survival and low-grade glioma: the emergence of genetic information. Neurosurgical Focus, 2015, 38, E6.	2.3	358
87	Telomere maintenance and the etiology of adult glioma. Neuro-Oncology, 2015, 17, 1445-1452.	1.2	70
88	Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology, 2015, 17, 1051-1063.	1.2	178
89	Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. Journal of Neurosurgery, 2015, 123, 325-339.	1.6	334
90	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell, 2015, 28, 307-317.	16.8	221

#	Article	IF	CITATIONS
91	Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget, 2015, 6, 42468-42477.	1.8	87
92	Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro-Oncology, 2014, 16, 1255-1262.	1.2	44
93	Effect of Provider Experience on Clinician-Performed Ultrasonography for Hydronephrosis in Patients With Suspected Renal Colic. Annals of Emergency Medicine, 2014, 64, 269-276.	0.6	60
94	Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nature Genetics, 2014, 46, 731-735.	21.4	161
95	A Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups. Biometrics, 2012, 68, 1146-1156.	1.4	21
96	Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation, 2011, 91, 1253-1261.	3.7	55
97	Power of Data Mining Methods to Detect Genetic Associations and Interactions. Human Heredity, 2011, 72, 85-97.	0.8	21
98	Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. Journal of the National Cancer Institute, 2010, 102, 627-637.	6.3	304
99	<i>partDSA</i> : deletion/substitution/addition algorithm for partitioning the covariate space in prediction. Bioinformatics, 2010, 26, 1357-1363.	4.1	37
100	Prediction error estimation: a comparison of resampling methods. Bioinformatics, 2005, 21, 3301-3307.	4.1	1,045
101	Tree-based multivariate regression and density estimation with right-censored data. Journal of Multivariate Analysis, 2004, 90, 154-177.	1.0	52